Drugs / VSA012
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06848296 | Apr 2025 → Feb 2027 expected | paroxysmal nocturnal hemoglobinuria | Bisirna Therapeutics Pte. Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06766929 | Jan 2025 → Aug 2026 overdue | — | Bisirna Therapeutics (Suzhou) Co., Ltd. | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-01-21 | Visirna Therapeutics HK Limited | Visirna Announces Dosing of the First Subjects in China Phase I Study of VSA012 visirna.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSA012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06848296 ↗ |